Last checked at 
21 Nov 2019 15:45
LEI: 549300Q7EXQQH6KF7Z84
21 November 2019
RTW Venture Fund Limited
RTW leads $100 Million Series C Financing in Avidity Biosciences
RTW Venture Fund Limited (the "Company") notes the announcement by Avidity Biosciences, Inc. ("Avidity Biosciences"), a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) for the treatment of rare muscle disorders and other serious diseases, of its completion of a $100 million Series C financing.
The Company, together with other funds managed by its investment manager, RTW Investments, LP, led the financing round. Roderick T. Wong, M.D., managing partner of RTW Investments, LP, will join Avidity Biosciences' board of directors.
"Our investment team is excited about Avidity Biosciences' first-in-class therapy for myotonic dystrophy, and the potential of its AOC platform to deliver RNA-based therapeutics to muscle and create transformative treatments for diseases with high unmet need," said Dr. Wong.
The announcement can be accessed on Avidity Biosciences' website at: https://www.aviditybiosciences.com and full text of the announcement from Avidity Biosciences is contained below.
The intention to invest in Avidity Biosciences was disclosed in the Company's prospectus dated 14 October 2019.
For Further Information
RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business OfficerAlexandra Taracanova, PhD, Director of Investor Relations
Julia Enright, Business Development Associate
Brunswick +44 (0)20 7404 5959Charis Gresser
Ayesha Bharmal
Avidity Biosciences Completes $100 Million Series C Financing
La Jolla, Calif., November 13, 2019 (BUSINESS WIRE) - Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) for the treatment of rare muscle disorders and other serious diseases, announced the completion of a $100 million Series C financing.
The financing was led by RTW Investments and included new investors Cormorant Asset Management, LP, CureDuchenne, Logos Capital, Perceptive Advisors LLC and ST Pharm. Existing investors also participated and include Alethea Capital, Alexandria Venture Investments, Boxer Capital of Tavistock Group, Brace Pharma Capital, EcoR1 Capital, Partner Fund Management and Takeda Ventures. Eli Lilly and Company contributed $15 million to the financing in connection with the research collaboration between Lilly and Avidity initiated in April 2019. Roderick T. Wong, M.D., managing partner of RTW Investments, will join Avidity Biosciences' board of directors.
"Avidity pioneered AOC technology that combines two powerful technologies: monoclonal antibodies for effective delivery and oligonucleotide therapeutic for potent and selective activity," said Sarah Boyce, president and CEO of Avidity Biosciences. "Using our AOC platform, we can unlock new potential for RNA therapeutics by efficiently targeting muscle and immune cells. These funds will enable Avidity to advance our growing proprietary portfolio of multiple programs, including our AOC treatment of myotonic dystrophy type I, to treat serious muscle disorders."
"Our investment team is excited about Avidity's first-in-class therapy for myotonic dystrophy, and the potential of its AOC platform to deliver RNA-based therapeutics to muscle and create transformative treatments for diseases with high unmet need," said Dr. Wong. "As a member of the board, I look forward to supporting the advancement of their pipeline into the clinic."
Dr. Wong is the founder of RTW Investments and is responsible for managing the firm's investments focused on innovative drug development. Prior to forming RTW, he was a managing director and sole portfolio manager for the Davidson Kempner Healthcare Funds. Before this, he held various healthcare investment and research roles at Sigma Capital and Cowen & Company. Dr. Wong received his medical doctorate from the University of Pennsylvania Medical School and an MBA from Harvard Business School, as well as a bachelor's degree in economics from Duke University.
SVB Leerink acted as lead financial advisor for Avidity Biosciences' Series C financing.
About Avidity Biosciences
Avidity Biosciences, Inc. is a privately-held biotech company pioneering Antibody-Oligonucleotide Conjugates (AOC™) for treatment of rare muscle disorders and other serious diseases. AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to enable more effective targeting of tissues, such as skeletal muscle, immune cells, and heart to create a pipeline of targeted oligonucleotide therapeutics. The company's lead research program addresses myotonic dystrophy type I, a disease with no approved treatment options. In April 2019, Avidity Biosciences and Eli Lilly announced a strategic partnership to utilize Avidity's AOC technology to pursue therapeutic targets initially focused on immunology and other indications. For more information, please visit www.aviditybio.com.
Contacts:
Company:
Leslie Ann Kerins
(858) 401-7900
leslie@aviditybio.com
Media:
Ian Stone
Senior Vice President
Canale Communications
(619) 849-5388
ian@canalecomm.com